Robert Ross, Surface Oncology CEO
November 2, 2022 11:04 AM EDTUpdated 03:46 PM
People
R&D

Sur­face On­col­o­gy lays off 20% as biotech halts CD39 work on one of its ‘crown jew­els’

Kyle LaHucik

Senior Reporter

Sur­face On­col­o­gy is let­ting go of 20% of its work­force as the biotech prunes its pipeline and nar­rows the scope of its lead drug. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Q&A: Demis Has­s­abis talks win­ning the No­bel Prize, build­ing an AI biotech sans lab, and Trump’s po­ten­tial im­pact

Sarep­ta dis­con­tin­ues work on next-gen ex­on-skip­ping drug for Duchenne

Biotech in­dus­try wor­ries over po­ten­tial for RFK Jr. al­ly as FDA pick

Mod­er­na re­ports slow start to RSV sales as Ban­cel steps back from com­mer­cial role

Avid Bioser­vices to be sold to pri­vate eq­ui­ty firms for $1.1B

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times